

## **IMMUNE-MEDIATED LIVER DISEASE SPECIAL INTEREST GROUP (SIG): ANNUAL REPORT 2018-19**

This annual report covers the period 1 December 2018 to 31 August 2019.

### **Membership**

The BASL Committee appointed an initial SIG Lead to serve for one year, Dr Palak Trivedi, Consultant Hepatologist, University Hospitals Birmingham. An election for the position of SIG lead will be held in 2019-20. The SIG has a Steering Committee, comprising the Lead and 12 other members, including four patient representatives. At the time of writing this report, there are 159 individuals included in the member database. 137 (86%) are BASL members and 22 (14%) are non-members.

### **Meetings**

The inaugural meeting of the SIG was held during 2018-19 - 11 July 2019, Birmingham, 41 participants.

### **Key achievements / action points**

#### ***Observational cohort studies in development:***

Each project will have a nominated principal investigator and designated research fellow.

- 1) Nationwide experience and outcomes of overlap presentations in autoimmune liver disease *Omar El-Sherif, Birmingham/Dublin*
- 2) Impact of AILD on sexual dysfunction and relationship status *Michael Heneghan, London*
- 3) Stratification of high-risk groups toward developing recurrent PSC *James Ferguson, Birmingham*
- 4) Epidemiological survey of patients with IgG4-RD in the UK *Emma Culver, Oxford*

#### ***Grants awarded in 2019 (applicable to the SIG):***

- 1) The PSC 600 initiative *Palak Trivedi, Birmingham*. This study is eligible for NIHR portfolio adoption. Press release to coincide with launch.
- 2) Real world need and comparative outcomes of second-line therapy in PBC *Palak Trivedi, Birmingham*
- 3) The EXCITED Study: Exercise Intervention in Cholestatic Liver Disease *Palak Trivedi, Birmingham*. This study is NIHR portfolio adopted.

#### ***Grant bids in development:***

- 1) EASL registry grant: checkpoint-inhibitor induced liver injury *Palak Trivedi, Birmingham*.
- 2) NIHR HS&DR scheme: Effective, efficient and equitable management in AILD *Palak Trivedi, Birmingham; George Mells, Cambridge; Jessica Dyson, Newcastle; David Jones, Newcastle*
- 3) NIHR HTA scheme: Optimised primary therapy in PBC *David Jones, Newcastle*

### **Further information**

Please visit the SIG webpage at <https://www.basl.org.uk/index.cfm/content/page/cid/39>.